Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Aquestive Therapeutics (AQST) one of those stocks right now? By taking a look at ...

Aquestive Therapeutics shares surged 137.29% (YoY) after FDA approval of rival company ARS Pharmaceutical's "epinephrine nasal spray" Neffy. Market optimism surrounds AQST’s robust R&D pipeline, with ...

We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a look at where Aquestive Therapeutics, Inc. (NASDAQ:AQST) stands against ...

Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.

It has been over six months since my previous Aquestive Therapeutics (AQST) article, where I discussed Anaphylm's potential approval and some of the possible catalysts along the way to their FDA PDUFA ...

Aquestive Therapeutics (NASDAQ:AQST) is preparing to release its quarterly earnings on Wednesday, 2026-03-04. Here's a brief overview of what investors should keep in mind before the announcement.

Aquestive Therapeutics (AQST) reported $11.87 million in revenue for the quarter ended December 2024, representing a year-over-year decline of 10.2%. EPS of -$0.19 for the same period compares to ...